References
Aspinall MG, Hamermesh RG (2007) Realizing the promise of personalised medicine. Harvard
Bus Rev.www.hbrreprints.org. October, pp 1–9
Astley SB (2007) An introduction to nutrigenomics developments and trends. Genes Nutr 2:11–13
Bosˇnjak H, Pavelic ́K, Kraljevic ́Pavelic ́S (2008) Towards preventive medicine. High-throughput
methods from molecular biology are about to change daily clinical practice. EMBO Rep
9:1056–1060
Catchpoole DR, Kennedy P, Scillicorn DR et al (2010) The curse of dimensionality: a blessing to
personalized medicine. J Clin Oncol 28:e723–e724
Clark GM, Zborowski DM, Culbertson JL et al (2006) Clinical utility of epidermal growth factor
receptor expression for selecting patients with advanced non-small cell lung cancer for
treatment with erlotinib. J Thorac Oncol 1:837–846
Editorial (2003) Nanomedicine: grounds for optimism. Lancet 362:673
Espina V, Dettloff KA, Cowherd S et al (2004) Use of proteomic analysis to monitor responses to
biological therapies. Expert Opin Biol Ther 4:83–93
ESF Forward Look (2012) Personalised medicine for the European citizen. Towards more precise
medicine for the diagnosis, treatment and prevention of disease (iPM). European Science
Foundation, Strasburg
European Science Foundation (2005) Nanomedicine. An ESF-European Medical Research Coun-
cils (EMRC) Forward look report, ESF, Strasbourg, France
Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer
5:161–171
Goldstein DB, Tate SK, Sisodiya SM (2003) Pharmacogenetics goes genomic. Nat Rev Genet
4:937–947
Hewitt RE (2011) Biobanking: the foundation of personalized medicine. Curr Opin Oncol 23
(1):112–119
Huser V, Sincan M, Cimino JJ (2014) Developing genomic knowledge bases and databases to
support clinical management: current perspectives. Pharmgenomics Pers Med 7:275–283
Kralj M, Pavelic ́K (2003) Medicine on a small scale. How molecular medicine can benefit from
self-assembled and nanostructured materials? EMBO Rep 4:1008–1012
Kraljevic ́S, Pavelic ́K (2005) Navigare necesse est. EMBO Rep 6:695–700
Kraljevic ́S, Stambrook PJ, Pavelic ́K (2004) Accelerating drug discovery. EMBO Rep 5:837–842
Kraljevic S, Sedic M, Scott M et al (2006) Casting light on molecular events underlying anti-
cancer drug treatment: what can be seen from the proteomics point of view? Cancer Treat Rev
32:619–629
Li X, Quigg RJ, Zhou J et al (2008) Clinical utility of microarrays: current status, existing
challenges and future outlook. Curr Genomics 9:466–474
M€uller M, Kersten S (2003) Nutrigenomics: goals and perspectives. Nat Rev Genet 4:315–322
Pavelic ́K, Martinovic ́T, Kraljevic ́Pavelic ́S (2014) Translational and personalized medicine. In:
Kraljic ́S, Rebersˇek-Gorisˇek, J, Rijavec V (eds) Medicina in pravo, Sodobne dileme III.
Univerza u Mariboru, Maribor, pp 255–263
Pavelic ́K, Martinovic ́T, Kraljevic ́Pavelic ́S (2015) Do we understand the personalized medicine
paradigm? EMBO Rep 16:133–136
Petricoin EF, Zoon KC, Kohn EC et al (2002) Clinical proteomics: translating benchside promise
into bedside reality. Nat Rev Drug Discov 1:683–695
Ries NM, Castle D (2008) Nutrigenomics and ethics interface: direct-to-consumer services and
commercial aspects. OMICS 12(4):245–250
Sedic ́M, Pavelic ́K, Josic ́D, Kraljevic ́Pavelic ́S (2014) Peptidomics to study age-related diseases:
spotlight on cancer and neurodegeneration. Peptidomics 1:65–76
Spaventi R, Pecˇur L, Pavelic ́K et al (1994) Human tumour bank in Croatia: a possible model for a
small bank as a part of the future European tumour bank network. Eur J Cancer 30A:419
18 K. Pavelic ́et al.